Download PDF
Semin Thromb Hemost 2023; 49(02): 111-118
DOI: 10.1055/s-0042-1758116
Review Article

Hypercoagulability and Thrombosis Risk in Prostate Cancer: The Role of Thromboelastography

Karina Fainchtein
1   Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
,
Yousra Tera
1   Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
2   Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
,
Natalie Kearn
1   Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
,
Abdelrahman Noureldin
1   Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
,
Maha Othman
1   Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
2   Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3   School of Baccalaureate Nursing, St. Lawrence College, Kingston, Ontario, Canada
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Thrombosis is one of the leading causes of death in cancer. Cancer-induced hypercoagulable state contributes to thrombosis and is often overlooked. Prostate cancer may not be of high thrombogenic potential compared with other cancers, but its high prevalence brings it into focus. Pathological evidence for venous thromboembolisms (VTEs) in prostate cancer exists. Factors such as age, comorbidities, and therapies increase the VTE risk further. There is a need to systematically identify the risk of VTE in regard to patient-, cancer-, and treatment-related factors to risk stratify patients for better-targeted and individualized strategies to prevent VTE. Sensitive tests to enable such risk assessment are urgently required. There is sufficient evidence for the utility of thromboelastography (TEG) in cancer, but it is not yet part of the clinic and there is only limited data on the use of TEG in prostate cancer. One study revealed that compared with age-matched controls, 68.8% of prostate cancer patients demonstrated hypercoagulable TEG parameters. The absence of clinical guidelines is a limiting factor in TEG use in the cancer population. Cancer heterogeneity and the unique cancer-specific microenvironment in each patient, as well as determining the hypercoagulable state in each patient, are added limitations. The way forward is to combine efforts to design large multicenter studies to investigate the utility and clinical effectiveness of TEG in cancer and establish longitudinal studies to understand the link between hypercoagulable state and development of thrombosis. There is also a need to study low thrombogenic cancers as well as high thrombogenic ones. Awareness among clinicians and understanding of test applicability and interpretation are needed. Finally, expert discussion is critical to identify the investigation priorities.

Keywords

coagulation - thromboelastography - thrombosis - hemostasis - prostate cancer


Publication History

Article published online:
21 November 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Campello E, Henderson MW, Noubouossie DF, Simioni P, Key NS. Contact system activation and cancer: new insights in the pathophysiology of cancer-associated thrombosis. Thromb Haemost 2018; 118 (02) 251-265
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Kaur H, Siemens DR, Black A. et al. Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: a prospective, longitudinal study. Can Urol Assoc J 2017; 11 (1-2): 33-38
    CrossrefPubMedGoogle Scholar
  • 3 Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996; 47: 315-331
    CrossrefPubMedGoogle Scholar
  • 4 Lwaleed BA, Lam L, Lasebai M, Cooper AJ. Expression of tissue factor and tissue factor pathway inhibitor in microparticles and subcellular fractions of normal and malignant prostate cell lines. Blood Coagul Fibrinolysis 2013; 24 (03) 339-343
    CrossrefPubMedGoogle Scholar
  • 5 Mitrugno A, Tormoen GW, Kuhn P, McCarty OJ. The prothrombotic activity of cancer cells in the circulation. Blood Rev 2016; 30 (01) 11-19
    CrossrefPubMedGoogle Scholar
  • 6 Chargari C, Vedrine L, Bauduceau O. et al. [Prostate cancer and disseminated intravascular coagulation: review of the literature]. Prog Urol 2008; 18 (01) 9-13
    CrossrefPubMedGoogle Scholar
  • 7 Unruh D, Horbinski C. Beyond thrombosis: the impact of tissue factor signaling in cancer. J Hematol Oncol 2020; 13 (01) 93
    CrossrefPubMedGoogle Scholar
  • 8 Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27 (29) 4834-4838
    CrossrefPubMedGoogle Scholar
  • 9 Pearson JD. Endothelial cell function and thrombosis. Baillieres Clin Haematol 1994; 7 (03) 441-452
    CrossrefPubMedGoogle Scholar
  • 10 Müller I, Klocke A, Alex M. et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17 (03) 476-478
    CrossrefPubMedGoogle Scholar
  • 11 Levitan N, Dowlati A, Remick SC. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78 (05) 285-291
    CrossrefPubMedGoogle Scholar
  • 12 Falati S, Liu Q, Gross P. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197 (11) 1585-1598
    CrossrefPubMedGoogle Scholar
  • 13 Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107 (23, Suppl 1): I17-I21
    PubMedGoogle Scholar
  • 14 Lloyd-Donald P, Vasudevan A, Angus P. et al. Comparison of thromboelastography and conventional coagulation tests in patients with severe liver disease. Clin Appl Thromb Hemost 2020; 26: 1076029620925915
    CrossrefPubMedGoogle Scholar
  • 15 Tur Martínez J, Petrone P, Axelrad A, Marini CP. Comparison between thromboelastography and conventional coagulation test: Should we abandon conventional coagulation tests in polytrauma patients?. Cir Esp (Engl Ed) 2018; 96 (07) 443-449
    PubMedGoogle Scholar
  • 16 Jeger V, Willi S, Liu T. et al. Comparison of point-of-care thrombelastography versus conventional coagulation tests in the emergency department management of trauma. Crit Care 2011; 15: 438
    CrossrefPubMedGoogle Scholar
  • 17 National Library of Medicine (U.S.). (February 2016 to March 2018). TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed: An Open Label Randomized Controlled Trial. Identifier NCT02689232. Accessed September 30, 2022 at: https://clinicaltrials.gov/ct2/show/NCT02689232
    PubMedGoogle Scholar
  • 18 Heidrich H, Konau E, Hesse P. Asymptomatic venous thrombosis in cancer patients – a problem often overlooked. Results of a retrospective and prospective study. Vasa 2009; 38 (02) 160-166
    CrossrefPubMedGoogle Scholar
  • 19 Ording AG, Horváth-Puhó E, Lash TL. et al. Prostate cancer, comorbidity, and the risk of venous thromboembolism: a cohort study of 44,035 Danish prostate cancer patients, 1995-2011. Cancer 2015; 121 (20) 3692-3699
    CrossrefPubMedGoogle Scholar
  • 20 Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH. [Androgen deprivation for advanced prostate cancer]. Urologe A 2008; 47 (03) 270-283
    PubMedGoogle Scholar
  • 21 Fernández JA, Heeb MJ, Radtke KP, Griffin JH. Potent blood coagulant activity of human semen due to prostasome-bound tissue factor. Biol Reprod 1997; 56 (03) 757-763
    CrossrefPubMedGoogle Scholar
  • 22 Stattin P, Holmberg E, Johansson J-E, Holmberg L, Adolfsson J, Hugosson J. National Prostate Cancer Register (NPCR) of Sweden. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102 (13) 950-958
    CrossrefPubMedGoogle Scholar
  • 23 Kłapcińska B, Jagsz S, Sadowska-Krępa E, Górski J, Kempa K, Langfort J. Effects of castration and testosterone replacement on the antioxidant defense system in rat left ventricle. J Physiol Sci 2008; 58 (03) 173-177
    CrossrefPubMedGoogle Scholar
  • 24 Roşca AE, Vlădăreanu AM, Mititelu A. et al. Effects of exogenous androgens on platelet activity and their thrombogenic potential in supraphysiological administration: a literature review. J Clin Med 2021; 10 (01) 147
    CrossrefPubMedGoogle Scholar
  • 25 Cohen T, Haas T, Cushing MM. The strengths and weaknesses of viscoelastic testing compared to traditional coagulation testing. Transfusion 2020; 60 (Suppl. 06) S21-S28
    PubMedGoogle Scholar
  • 26 Wang Z, Li J, Cao Q, Wang L, Shan F, Zhang H. Comparison between thromboelastography and conventional coagulation tests in surgical patients with localized prostate cancer. Clin Appl Thromb Hemost 2018; 24 (05) 755-763
    CrossrefPubMedGoogle Scholar
  • 27 The Exert steering group meeting. The White Paper on Cancer Associated Thrombosis, Brussels, December 11–15, 2015. Accessed September 30, 2022 at: https://ecpc.org/wp-content/uploads/2020/10/Cancer-Associated-Thrombosis-White-Paper-final.pdf
    PubMedGoogle Scholar
  • 28 Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 626-630
    CrossrefPubMedGoogle Scholar
  • 29 Monreal M, Falgá C, Valdés M. et al; RIETE Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4 (09) 1950-1956
    CrossrefPubMedGoogle Scholar
  • 30 Maraveyas A, Johnson M. Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?. Br J Cancer 2009; 100 (12) 1837-1841
    CrossrefPubMedGoogle Scholar
  • 31 Marrinucci D, Bethel K, Kolatkar A. et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012; 9 (01) 016003
    CrossrefPubMedGoogle Scholar
  • 32 Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65 (04) 1406-1413
    CrossrefPubMedGoogle Scholar
  • 33 Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206 (09) 1913-1927
    CrossrefPubMedGoogle Scholar
  • 34 Mao C, Xiong Y, Fan C. Comparison between thromboelastography and conventional coagulation assays in patients with deep vein thrombosis. Clin Chim Acta 2021; 520: 208-213
    CrossrefPubMedGoogle Scholar
  • 35 Hartert H. Blood clotting studies with thrombus stressography; a new Investigation procedure. Klin Wochenschr 1948; 26 (37-38): 577-583
    PubMedGoogle Scholar
  • 36 Othman M, Kaur H. Thromboelastography (TEG). Methods Mol Biol 2017; 1646: 533-543
    CrossrefPubMedGoogle Scholar
  • 37 Quan X, Qin Q, Que X. et al. Utility of thromboelastography to identify hypercoagulability in lung cancer related ischemic stroke patients. Clin Appl Thromb Hemost 2020; 26: 1076029620975502
    CrossrefPubMedGoogle Scholar
  • 38 Shi Z, Zheng WC, Fu XL, Fang XW, Xia PS, Yuan WJ. Hypercoagulation on thromboelastography predicts early neurological deterioration in patients with acute ischemic stroke. Cerebrovasc Dis 2018; 46 (3-4): 125-131
    PubMedGoogle Scholar
  • 39 Kupcinskiene K, Trepenaitis D, Petereit R. et al. Monitoring of hypercoagulability by thromboelastography in bariatric surgery. Med Sci Monit 2017; 23: 1819-1826
    CrossrefPubMedGoogle Scholar
  • 40 Rosafio F, Vandelli L, Bigliardi G. et al. Usefulness of thromboelastography in the detection and management of tissue plasminogen activator-associated hyperfibrinolysis. J Stroke Cerebrovasc Dis 2017; 26 (02) e29-e31
    CrossrefPubMedGoogle Scholar
  • 41 National Library of Medicine (U.S.). (December 2016 to December 2018). Management of Coagulopathy in Cirrhotic Patients Undergoing Invasive Procedures: a Prospective Trial Comparing Standard Management to Thromboelastography Protocol Based Management. Identifier NCT02987712. Accessed September 30, 2022 at: https://clinicaltrials.gov/ct2/show/NCT02987712
    PubMedGoogle Scholar
  • 42 Toukh M, Siemens DR, Black A. et al. Thromboelastography identifies hypercoagulability and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 2014; 133 (01) 88-95
    CrossrefPubMedGoogle Scholar
  • 43 Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. Thromb Res 1994; 74 (04) 335-346
    CrossrefPubMedGoogle Scholar
  • 44 Gong C, Yu K, Zhang N, Huang J. Predictive value of thromboelastography for postoperative lower extremity deep venous thrombosis in gastric cancer complicated with portal hypertension patients. Clin Exp Hypertens 2021; 43 (02) 196-202
    CrossrefPubMedGoogle Scholar
  • 45 Agha AM, Gill C, Balanescu DV. et al. Identifying hemostatic thresholds in cancer patients undergoing coronary angiography based on platelet count and thromboelastography. Front Cardiovasc Med 2020; 7: 9
    CrossrefPubMedGoogle Scholar
  • 46 Zhou Y, Guo Y, Cui Q. et al. Application of thromboelastography to predict lung cancer stage. Technol Cancer Res Treat 2020; 19: 1533033820952351
    CrossrefPubMedGoogle Scholar
  • 47 Laskov I, Grisaru D, Deutsch V, Fargo N, Raz Y, Mishaan N. Evaluation of the hypercoagulable state of gynecologic cancer patients by thromboelastography: a prospective pilot study and a review of the literature. Eur J Gynaecol Oncol 2019; 40 (06) 988-993
    CrossrefPubMedGoogle Scholar
  • 48 Wehrum MJ, Hines JF, Hayes EB, Kost ER, Hall KL, Paidas MJ. Comparative assessment of hypercoagulability in women with and without gynecologic malignancies using the thromboelastograph coagulation analyzer. Blood Coagul Fibrinolysis 2010; 21 (02) 140-143
    CrossrefPubMedGoogle Scholar
  • 49 Schulick A, Moore H, Friedman C. et al. New angle on pancreatic cancer: Is thromboelastography superior to CA19–9 as a prognostic tool to predict early recurrence after pancreatectomy?. J Am Coll Surg 2019; 229 (04) S269-S270
    CrossrefPubMedGoogle Scholar
  • 50 Amirkhosravi A, Bigsby IV G, Desai H. et al. Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses. Blood Coagul Fibrinolysis 2013; 24 (05) 510-517
    CrossrefPubMedGoogle Scholar
  • 51 Wang X, Shi A, Huang J, Chen Y, Xue W, Zhang J. Assessment of hypercoagulability using thromboelastography predicts advanced status in renal cell carcinoma. J Clin Lab Anal 2020; 34 (01) e23017
    CrossrefPubMedGoogle Scholar
  • 52 Gautham N. Evaluation of Coagulation profile in Primary Brain tumors in the Perioperative period using Thromboelastography. Doctoral dissertation, 2017; Sree Chitra Tirunal Institute for Medical Sciences & Technology.
    PubMedGoogle Scholar